FDA Brief

Warning letters Drugs

FDA warning letter to

MexHealth LLC d/b/a Al Natural E-Shop

High riskIssued Aug 27, 2024Posted Sep 3, 2024Center for Drug Evaluation and Research (CDER)

FDA warned MexHealth LLC d/b/a Al Natural E-Shop that its Ossos-Sans supplement is an unapproved, misbranded drug containing hidden diclofenac and methocarbamol.

What happened

FDA reviewed the company's website in April 2024 and July 2024 and obtained samples and labeling of Ossos-Sans. Laboratory analysis found the product contained undeclared diclofenac and methocarbamol. The website and labeling marketed it as a dietary supplement for arthritis, osteoporosis, inflammation, and other conditions.

What FDA found

  1. The product is a new drug without an FDA-approved application, so it cannot be legally sold across state lines.

    FD&C Act §§ 505(a), 301(d), 21 U.S.C. §§ 355(a), 331(d)
  2. The labeling does not disclose that the product contains diclofenac and methocarbamol, making it misbranded.

    FD&C Act § 502(a), 21 U.S.C. § 352(a); § 201(n), 21 U.S.C. § 321(n)
  3. The product is labeled as a dietary supplement, but it contains diclofenac, a drug ingredient approved before it was marketed as a supplement, so it falls outside the dietary supplement definition.

    FD&C Act § 201(ff)(3)(B)(i), 21 U.S.C. § 321(ff)(3)(B)(i)
  4. The label claims the product treats arthritis, osteoporosis, inflammation, fractures, and other conditions, which shows it is intended as a drug.

    FD&C Act § 201(g)(1), 21 U.S.C. § 321(g)(1)
  5. The product is misbranded because its labeling fails to reveal material facts about the hidden drug ingredients.

    FD&C Act § 502(a), 21 U.S.C. § 352(a)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of receipt with the specific corrective steps, how it will prevent recurrence, related documentation, or its reasoning and evidence if it believes there is no violation.

Who should pay attention

  • online shoppers buying arthritis or pain supplements
  • retailers and online marketplaces selling supplements
  • supplement brands and distributors relying on supplier labels

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  2. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk
  3. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  4. C & A Naturistics

    C & A Naturistics sold unapproved new drugs online, including AK Forte with hidden acetaminophen and diclofenac.

    High risk